ERBB2 and breast carcinoma: These results show that temsirolimus could have a relevant effect in patients with HER2 breast cancer, even those that have progressed to anti-HER2 therapies, and combination with FASN-inhibitors could even assist temsirolimus to achieve tumor depletion.